Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_assertion type Assertion NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_head.
- NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_assertion description "[To better understand the molecular mechanisms of the antiproliferative action of this BK antagonist in EOC cells, we performed gene expression profiling in TOV-21 and TOV-112 cells following treatment with 10 ?M BKM-570 for 24 h. BKM-570 displayed similar cytotoxic effects in the two cell lines analyzed, as genes with previously shown involvement in apoptosis/antiapoptosis and cell adhesion were proportionally upregulated and downregulated in both cell lines, whereas genes involved in basic cellular mechanisms, including cell growth and maintenance, metabolism, cell cycle control, inflammatory and immune response, signal transduction, protein biosynthesis, transcription regulation, and transport, were predominantly downregulated upon treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_provenance.
- NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_assertion evidence source_evidence_literature NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_provenance.
- NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_assertion SIO_000772 21078129 NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_provenance.
- NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_assertion wasDerivedFrom befree-20150227 NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_provenance.
- NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_assertion wasGeneratedBy ECO_0000203 NP526731.RAB4gXeirQWwMJDNvQtelGRlmGV5G-35q3m3dQQVe_k5M130_provenance.